International Public

Home > Spobiotic > International Public

LiveSpo NAVAX’s report on Nature.com. (2023)

Tran, T.T., Phung, T.T.B., Tran, D.M. et al. Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics. Sci Rep 13, 14789 (2023). https://doi.org/10.1038/s41598-023-41763-5

LiveSpo NAVAX’s report on Nature.com. (2022)

Dien Minh Tran, Tu Thanh Tran, Thuy Thi Bich Phung, Huyen Thi Bui, Phuc Thanh Thi Nguyen, Tam Thi Vu, Nga Thi Phuong Ngo, Mai Thi Nguyen, Anh Hoa Nguyen & Anh Thi Van Nguyen (2022); Nasal-spraying Bacillus spores as an effective sympyomatic treatment for children with acute respiratory syncytial virus infection; Scientific Reports (2022) 12:12402, DOI: 10.1038/s41598-022-16136-z.

FDA NDI 1167 for LiveSpo COLON.

Bacillus clausii and Bacillus subtilis, under tradename LiveSpo® COLON – Ana Bio Research & Development JSC – 10/15/2020. Letter from FDA CFSAN to Ana Bio Research & Development JSC regarding NDI 1167 – LiveSpo COLON

LiveSpo NAVAX on the ClinicalTrials.gov - U.S. National Library of Medicine.

Effects of Nasal-spraying LiveSpo Navax in Treatment of Acute Respiratory Infections in Children.

LiveSpo DIA30 on the ClinicalTrials.gov - U.S. National Library of Medicine.

Effects of Probiotic in Treatment of Persistent Diarrhea in Children.

LiveSpo X-Secret on the ClinicalTrials.gov - U.S. National Library of Medicine.

Effects of LiveSpo X-secret in Supporting Treatment of Sexually Transmitted Diseases.